M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Drug: Aranesp (darbepoetin alfa)
Drug: Neulasta (pegfilgrastim)
Drug: Adriamycin
Drug: Ifosfamide

First Posted Date: 2006-01-30

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00283621

Locations: 🇺🇸
UT MDAnderson Cancer Center, Houston, Texas, United States

Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

Phase 3

Completed

Conditions: Sarcoma

First Posted Date: 2006-01-30

Last Posted Date: 2018-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00283582

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Procedure: Conventional surgery
Biological: PEG-interferon alfa-2b
Procedure: Neoadjuvant therapy

First Posted Date: 2006-01-13

Last Posted Date: 2012-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00276523

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab (Avastin)
Drug: Carboplatin
Drug: Docetaxel

First Posted Date: 2006-01-02

Last Posted Date: 2020-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT00271505

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Breast Cancer

Interventions: Drug: CT-2103
Drug: Gemcitabine

First Posted Date: 2005-12-29

Last Posted Date: 2013-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00270907

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Lenalidomide

First Posted Date: 2005-12-20

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00267059

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Minimal Residual Disease

Interventions: Biological: Synthetic Tumor-Specific Breakpoint Peptide Vaccine

First Posted Date: 2005-12-20

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00267085

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Phase 2

Completed

Conditions: Sarcoma
Oral Mucositis

Interventions: Drug: Placebo
Drug: Palifermin
Drug: Adriamycin (Doxorubicin)
Drug: Ifosfamide
Drug: Vincristine
Drug: Cisplatin

First Posted Date: 2005-12-20

Last Posted Date: 2012-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00267046

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Mastocytosis
Myelodysplastic Syndromes
Agnogenic Myeloid Metaplasia
Myelofibrosis
Polycythemia Vera
Hypereosinophilic Syndrome
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Dasatinib (BMS-354825)

First Posted Date: 2005-11-18

Last Posted Date: 2023-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT00255346

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Interventions: Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2005-11-16

Last Posted Date: 2025-03-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 156

Registration Number: NCT00254423

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy